Peficitinib
| CAS No. | 944118-01-8 | Cat. No. | BCP18465 |
| Name | Peficitinib | ||
| Synonyms | ASP015K;JNJ-54781532;ASP-015K;ASP 015K;JNJ54781532;JNJ 54781532; | ||
| Formula | C18H22N4O2 | M. Wt | 310.39 |
| Description | Peficitinib (ASP015K) is a novel orally bioavailable JAK inhibitor in development for the treatment of severe rheumatoid arthritis (RA). Milder inhibition of JAK2 by Peficitinib may contribute to the mitigation of effects on red blood cells and platelets reported to be caused by JAK2 inhibition. Moreover, Peficitinib has shown an improvement in symptoms in RA animal models after once-daily oral administration, and has demonstrated dose-dependent improvement in psoriatic disease activities in a 6-week phase IIa study. The terminal mean half-life of Peficitinib was estimated to be 7-13 h in pharmacological studies with healthy subjects, suggesting that Peficitinib can be dosed once-daily in the next development stage. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway Wnt/Stem Cell Epigenetics | ||
| Targets | JAK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.